What strategies are currently being used or explored to discover new alternatives to traditional antibiotics, and how effective have these strategies been in finding new drugs that can combat antimicrobial resistance?
May be this article is of use in addressing your query to some extent.
1.Article Computational antimicrobial peptide design and evaluation ag...
2. Article Strategies to Overcome Antimicrobial Resistance (AMR) Making...
3. Article Synergistic interactions of phytochemicals with antimicrobia...
Once I have been curious more about the synergistic interactions as we already know that our antimicrobial option are on the way of its limitations. Thank you.
According to Cui et al., 2021, combination therapy and repurposing of old drugs are great strategies against drug-resistant bacteria. These strategies provide an encouraging way to prolong the purpose of existing antibiotics. Combination therapy is a strategy that combines more than one method of treatment. For instance, taniborbactam and cefepime may be used to treat infections caused by Carbapenem-Resistant Enterobacterales (CRE) and Pseudomonas aeruginosa, and bioterrorist pathogens like Burkholderia spp. On the other hand, drug repurposing like fosfomycyin, which was discovered earlier but is not used frequently, contains a vast range of activities against multi-drug resistant organisms including Methicillin-resistant Staphylococcus aureus (MRSA),Vancomycin-resistant Enterococcus (VRE), and CRE. Other sources also stated that new therapies including antimicrobial peptides (AMPs), quorum sensing (QS),and new chemically synthesized molecules were cultivated to help bridge the ongoing drug resistance crisis.
Sources:
Cui X, Lü Y, Yue C. Development and Research Progress of Anti-Drug Resistant Bacteria Drugs. Infect Drug Resist. 2021;14:5575-5593 https://doi.org/10.2147/IDR.S338987
Pacios, O., Blasco, L., Bleriot, I., Fernandez-Garcia, L., González Bardanca, M., Ambroa, A., López, M., Bou, G., & Tomás, M. (2020). Strategies to Combat Multidrug-Resistant and Persistent Infectious Diseases. Antibiotics (Basel, Switzerland), 9(2), 65. https://doi.org/10.3390/antibiotics9020065